8 results on '"*METASTATIC breast cancer"'
Search Results
2. EE46 Cost-Effectiveness of Alpelisib Plus Fulvestrant in Postmenopausal Women with Hr+/HER2- Advanced Breast Cancer (ABC) in Oman.
3. EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC).
4. EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis.
5. EE372 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative Advanced/Metastatic Breast Cancer in Colombia.
6. POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia.
7. PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
8. PCN4 Overall Survival in Post-Menopausal Women with HR+/HER2- Advanced Breast Cancer Receiving a CDK 4 and 6 Inhibitor + Fulvestrant after Progressing on/after Prior Endocrine Therapy: A Fractional Polynomial Network Meta-Analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.